Morgan Stanley’s AEON Biopharma AEON Stock Holding History

Morgan Stanley’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$148	Hold	150	–	–	﹤0.01%	7735
2025 Q4	$165	Hold	150	–	–	﹤0.01%	7651
2025 Q3	$121	Hold	150	–	–	﹤0.01%	7656
2025 Q2	$114	Hold	150	–	–	﹤0.01%	7635
2025 Q1	$87	Sell	150 -1	-0.7%	-$7	﹤0.01%	7595
2024 Q4	$5.87K	Buy	151 +126	+504%	+$7.34K	﹤0.01%	6964
2024 Q3	$1.89K	Hold	25	–	–	﹤0.01%	7141
2024 Q2	$1.89K	Sell	25 -120	-83%	-$28.6K	﹤0.01%	7076
2024 Q1	$121K	Buy	145 +95	+190%	+$68.8K	﹤0.01%	5915
2023 Q4	$25.9K	Buy	+50	New	+$20.1K	﹤0.01%	6567

Other funds holding AEON

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley's AEON Position: Q1 2026 in Review

Morgan Stanley held its AEON Biopharma (AEON) position steady in Q1 2026 at 150 shares worth $148. The position accounts for ﹤0.01% of the portfolio, ranked #7735.

Morgan Stanley first reported a position in AEON in Q4 2023 and has held it in 10 quarters since. The position peaked at $121K in Q1 2024. 24 funds tracked by Wall St. Rank hold AEON as of Q1 2026.

Morgan Stanley held 150 shares of AEON Biopharma worth $148 as of Q1 2026.
Morgan Stanley left its AEON Biopharma share count unchanged in Q1 2026.
AEON Biopharma made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7735 holding.
Morgan Stanley first reported a position in AEON Biopharma in Q4 2023 and has held it in 10 quarters since.
Morgan Stanley's AEON Biopharma position peaked at $121K in Q1 2024.
24 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.